Aktuellt
SENASTE
Catalyst sales of SEK 16.7m (7% vs SEB 15.6) corresponding to 155% y/y growth was strong. The good momentum continues and more IDNs seems to be driving this. A new reporting style, more transparent, is welcomed as it gives us and investors a better view of the cost base. We note that R&D expenses are up 50% y/y which we believe has to do with enrollment to the clinical registry. We reiterate our DCF mid-point of SEK 9.
LÄS MER
